82 results about "Cryptococcus gattii" patented technology

The current invention relates to the field of detection and identification of clinically important fungi. More particularely, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cryptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.

The invention discloses a fruit disease antiseptic preservative agent, composed of cryptococcus laurentii suspension, pyrimethanil and water. Every 1L preservative agent contains 1*10<10>-1*10<11> cryptococcus laurentii cells, 4-400mg of pyrimethanil, and the balance of water. Preservation name of cryptococcus laurentii is Cryptococcus laurentii ZJU 10, preservation organism is China General Microbiological Culture Collection Center, preservation data is January 20, 2010, preservation number is CGMCC NO.3590, and preservation address is No.3, Courtyard 1, Beichen West road, Chaoyang District, Beijing, namely Institute of Microbiology of Chinese Academy of Sciences. The fruit disease antiseptic preservative agent has the characteristic that preservative effect is good.

The invention discloses a target gene, a primer and probes for detecting and identifying cryptococcus and a kit, which belong to the field of medical mycology. According to the target gene of the cryptococcus, the sequences of the primer for detecting a gene of the cryptococcus is designed, which are shown as SEQ ID No.3 and SEQ ID No. 4 and / or SEQ ID No. 6 and SEQ ID No. 7, wherein the SEQ ID No.3 and the SEQ ID No. 4 correspond to cryptococcus neoformans, the SEQ ID No. 6 and the SEQ ID No. 7 correspond to cryptococcus gattii; and the primer can be used for specific detection of the cryptococcus neoformans and the cryptococcus gattii. Based on the fluorogenic quantitative PCR (polymerase chain reaction) principle, the invention also provides a group of probes for detecting the cryptococcus neoformans and / or the cryptococcus gattii and the detection kit based on the primer and the probes, and the probes and the kit can be used for detecting the cryptococcus neoformans and the cryptococcus gattii that are pathogenic in a same system simultaneously or respectively. The target gene, the primer, the probes and the kit have the advantages of high sensibility, strong specificity, good repeatability and short detection time.

Strains of Cryptococcus flavescens which are superior antagonists of F. graminearum for suppression and control of FHB in cereals, particularly in wheat and barley, are described. The strains are prothioconazole tolerant variants of previously described C. flavescens OH 182.9 (NRRL Y-30216). Moreover, these prothioconazole tolerant variants exhibit significantly increased efficacy against F. graminearum in comparison to the parent strain OH 182.9.

The invention discloses a primer group for detecting respiratory tract microorganisms based on a nanopore sequencing method. The nucleotide sequences of the primer group are as shown in SEQ ID NO:1-20. The microorganisms are streptococcus pneumoniae, staphylococcus aureus (resisting to methicillin), klebsiella pneumoniae, pseudomonas aeruginosa, acinetobacter baumannii, stenotrophomonas maltophilia, candida albicans, haemophilus influenzae, legionella pneumophila, enterococcus faecium, chlamydia psittaci, cryptococcus gattii, aspergillus fumigatus and pneumocystis jiroveci. According to the invention, sequencing optimization is carried out on different types of samples of the respiratory tract microorganisms, so that the detection method, the kit and the like are suitable for various typesof respiratory tract samples; and a targeted amplification method is adopted, so that the detection requirements of sputum, alveolar lavage and other sample types can be met. In addition, parallel sequencing can be performed, so that the flux of the detected samples is increased, the sequencing time is shortened, and the contradiction between the flux of detected pathogenic species and the cost and time is further relieved.

The invention relates to an anti-cryptococcal capsular polysaccharide hybridoma cell strain and an anti-cryptococcal capsular polysaccharide monoclonal antibody secreted thereof. The antibody can be specifically bound to cryptococcal capsular polysaccharide and can be used for in vitro detection of cryptococcal infection. The antibody titer is up to more than one million, and the antibody has excellent affinity and good specific binding capability. The detection limit of a colloidal gold-labeled immunodiagnostic reagent developed with the antibody as the raw material is 0.5 ng / ml, and the antibody has excellent performance in sensitivity, specificity, stability and all other aspects.

The invention relates to primers capable of early diagnosis of cryptococcus infections and application thereof. The primers are designed by using an IGS1 sequence of the most common clinical strain of newborn cryptococcus in the world-H99 strain as a target sequence by utilizing LAMP (loop-mediated isothermal amplification) professional primer design software. The experiment on effectiveness, specificity and sensitivity proves that the primers can be used for early diagnosis of cryptococcus infections, have the advantages of high speed, simpleness, strong operability and convenient result identification, solve the problems of long time period for diagnosing cryptococcus infections, low requirements for detection personnel technique and laboratory platform conditions and the like, can be made into a kit, and provide convenience for early diagnosis and timely treatment of cryptococcus infections.

The present invention concerns methods of treating fungal infections and methods of screening compounds for activity in treating fungal infections. Methods of the invention include using an active compound such as fludioxonil to treat a Cryptococcus neoformans infection. Also included are methods and pharmaceutical compositions useful for treating fungal infections using a Hog1 activator such as fludioxonil and a calcineurin inhibitor in combination.

The invention discloses an antibacterial peptide Scybaumancin105-127 and application thereof, the antibacterial peptide is found in Scylla paramamosain for the first time, the molecular formula of the antibacterial peptide is C106H188N36O28S3, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO.1. The antibacterial peptide Scybaumancin105-127 disclosed by the invention has good antibacterial activity on acinetobacter baumannii, shigella flexneri, escherichia coli, pseudomonas aeruginosa, cryptococcus neoformans, listeria monocytogenes, enterococcus faecium and propionibacterium acnes, and has no cytotoxicity on normal cells. The antibacterial peptide Scybaumancin105-127 has high antibacterial activity, safety and non-toxic, also has relatively strong antibacterial activity on clinical drug-resistant bacteria, and has a wide application prospect.

The invention discloses design synthesis of a novel quinoline-2(1H) ketopiperazines compound and application thereof in the aspect of resisting microorganisms. The structure of the compound is shown in general formula I as shown in the description, and R1 and R2 groups are separately hydrogen, straight-chain or branched-chain alkyl consisting of 1-5 carbon atoms, cycloalkyl and heterocyclyl consisting of 3-8 carbon atoms and aryl; or the R1 and R2 groups and N atoms form 5-8-membered heterocycle or heteroaromatic ring and the like. Through biological activity test experiments on the synthesized compound, it proves that part of the compound has obvious inhibition activity to chitin synthetase, part of the compound has good inhibition activity to candida albicans, aspergillus flavus, novel cryptococcus neoformans and aspergillus fumigatus, and thus, the quinoline-2(1H) ketopiperazines compound can be used for preparing a drug for resisting pathogenic microorganisms.

The invention provides a voriconazole copper nitrate complex with bacteriostatic activity and a preparation method thereof. A synthesis method comprises the steps of dissolving voriconazole (FZ for short) and copper nitrate in a certain volume of water and organic solvent, cooling a reaction mixture to room temperature after heating is completed, carrying out filtering and standing so as to separate out a blue target product, and determining the crystal structure of the target product by monocrystalline X-rays; and the chemical formula of the product is [Cu(FZ)2(NO3)2]. Ultraviolet, infrared and antibacterial activities are further researched. The complex has high antibacterial activity to Achromobacter xylosoxidans, Bacillus subtilis, Candida glabrata, Cryptococcus neoformans, Aspergillus niger, Aspergillus fumigatus, Aspergillus flavus and the like. The compound can serve as an excellent novel antibacterial agent product.

The invention discloses a method for identifying cryptococcus neoformans and cryptococcus gattii by utilizing Raman scattering. According to the invention, distinguishing cryptococcus neoformans and cryptococcus gattii is taken as an entry point, and a detection method capable of enhancing Raman spectrum signals of the two fungi and distinguishing the two fungi is developed in a targeted manner. Results show that the surfaces of the two fungi are negatively charged, positive-valence colloidal silver can be well adsorbed, Raman detection signals of the fungi can be well enhanced by developing the positive-valence colloidal silver with a proper particle size, the fungi extremely close to the fungi can be identified, the method and the material are expected to be applied to more fungus detection, and development of clinical fungus identification is promoted.

The invention belongs to the field of fungal etiology detection, and discloses a primer and a probe for detecting cryptococcus, wherein the primer is a universal primer for detecting cryptococcus neoformans and cryptococcus gattii, and the probe comprises a probe for detecting cryptococcus neoformans and cryptococcus gattii. According to the invention, the raw materials required for detecting cryptococcus neoformans and cryptococcus gattii are put into the same reaction system, so that cryptococcus neoformans and cryptococcus gattii can be detected and identified at the same time, the varietyof pathogenic bacteria is clear, rapid and accurate clinical diagnosis is facilitated, and precious time is gained for disease treatment.

The invention provides a monoclonal antibody against Cryptococcus capsular polysaccharide, and an application thereof. A heavy chain variable region of the monoclonal antibody comprises an amino acidsequence as shown in SEQ ID NO:7; and a light chain variable region of the monoclonal antibody comprises an amino acid sequence as shown in SEQ ID NO:8. The monoclonal antibody of the invention is obtained from New Zealand big-ear rabbits, has relatively strong binding activity and neutralizing activity to the Cryptococcus capsular polysaccharide, has good stability, and can be potentially appliedto detection and identification of Cryptococcus infected clinical samples, development of Cryptococcus inhibitors, and the like.

The invention relates to the technical field of medical biological detection and provides a detection kit for the activity of cryptococcus. The kit adopts two types of fluorescent dyes to mark mycothallus and the activity of fungus respectively, and can analyze the quantity and the activity of the cryptococcus in cerebrospinal fluid fast and accurately by utilizing the kit and by means of assistance of a common flow cytometry. The invention also provides a detection method utilizing the detection kit for the activity of the cryptococcus and has important guiding significance for conducting prognosis to a patient and making the clinical treatment scheme.

The invention discloses LAMP primer combination for detecting two kinds of cryptococcus and application of the LAMP primer combination. The primer combination provided by the invention consists of 12primers as shown from sequence 1 to sequence 12. The primer combination provided by the invention can be applied to detect whether a sample to be detected contains cryptococcus neoformans and / or cryptococcus gattii. The primer combination identification provided by the invention is used for detecting two kinds of cryptococcus of cryptococci, has high specificity and high sensitivity, and can realize simple, convenient, fast and accurate detection. The LAMP primer combination has a significant promotional value.